| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | 968 | CTRPv2 | pan-cancer | AAC | 0.38 | 1e-09 |
| mRNA | myriocin | CTRPv2 | pan-cancer | AAC | 0.33 | 7e-06 |
| mRNA | TAE684 | CTRPv2 | pan-cancer | AAC | 0.15 | 1e-05 |
| mRNA | staurosporine | CTRPv2 | pan-cancer | AAC | 0.29 | 2e-05 |
| mRNA | Parthenolide | CTRPv2 | pan-cancer | AAC | 0.15 | 8e-05 |
| mRNA | PX-12 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.0003 |
| mRNA | tosedostat | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0004 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.11 | 0.0005 |
| mRNA | brivanib | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0007 |
| mRNA | BIBR-1532 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0007 |